Guggenheim Starts Assembly Biosciences (ASMB) at Buy

Guggenheim analyst Vamil Divan initiates coverage on Assembly Biosciences (NASDAQ: ASMB) with a Buy rating and a price target of $31.00.

For an analyst ratings summary and ratings history on Assembly Biosciences click here. For more ratings news on Assembly Biosciences click here.

Shares of Assembly Biosciences closed at $11.12 yesterday.

You May Also Be Interested In

• Trump Did Not Repeat Termination Of Interim Deal With Iran During Nato Summit, Source Familiar With The Talks Says - Reuters
• Alumis (ALMS) Reiterated at Overweight by Cantor Fitzgerald Ahead of Phase 2b SLE Readout
• Equifax (EFX) Reiterated at Buy by Stifel on Declared Intention to Acquire Circulo de Credito